Objectives: The aim of this study was to assess the diagnostic performance of a dynamic, multiphasic contrast-enhanced volume-interpolated sequence with advanced parallel imaging techniques, Dixon fat saturation, and view sharing with 5 hepatic arterial subphases for the detection of focal liver lesions. Materials and Methods: Twenty-four consecutive patients (13 females, 11 males; mean [SD] age, 58 [15] years) with focal liver lesions were included in this prospective study. The examination was performed at a 3-T magnetic resonance imaging system (MAGNETOM Skyra; Siemens Healthcare, Erlangen, Germany). Five dynamic arterial subphases with a temporal resolution of 2.6 seconds, starting 17 seconds after injection of the hepatobiliary contrast agent gadolinium ethoxybenzyl diethylenetriaminepentaacetic acid (Eovist; Bayer HealthCare, Leverkusen, Germany), were acquired using an accelerated parallel imaging volume-interpolated sequence with view sharing (multiarterial controlled aliasing in parallel imaging results in higher acceleration-Dixon-time-resolved angiography with interleaved stochastic trajectories-volumetric interpolated breath-hold examination [MA-CDT-VIBE]). The fourth of the 5 arterial acquisition phases (ie, at 24.8 seconds after the start of contrast agent injection) was considered the equivalent of a standard hepatic arterial phase (equivalent standard arterial phase [ESAP]). The diagnostic value of all 5 dynamic arterial phases for the detection of focal liver lesions, as compared with the single ESAP, was judged in 2 independent consensus readings. The 2 consensus reading groups were blinded to each others' results. The complete, comprehensive multisequence magnetic resonance imaging examination, including T1-weighted, T2-weighted, and multiphasic contrast-enhanced sequences, served as the standard of reference for lesion detection. Results: Forty-six percent of the patients (11/24) had hypervascular lesions. In 79 % of all patients (19/24), the best arterial parenchymal contrast of one of the MA-CDT-VIBE acquisition phases was considered better than that of the ESAP. In one third of all cases (8/24 for the first and 6/24 for the second consensus reading), MA-CDT-VIBE showed an improved lesion detection rate compared with ESAP, especially in hypervascular lesions (4/11, representing 36 % of all patients with hypervascular lesions). There was a high degree of interrater agreement between the 2 consensus reading groups (the Cohen κ, 0.71-1.00; P < 0.001). Conclusions: Compared with a standard hepatic arterial phase, MA-CDT-VIBE with 5 hepatic arterial subphases demonstrated greater diagnostic accuracy for the detection of hypervascular focal liver lesions and provided a robust and optimized hepatic arterial acquisition phase.
D
ynamic magnetic resonance imaging (MRI) of the liver using contrast-enhanced volumetric 3-dimensional T1-weighted fatsaturated gradient-recalled echo (T1w-3D-fs-GRE) sequences is considered the standard of reference for the diagnostic workup of focal liver lesions.
1,2 Sequences of T1w-3D-fs-GRE (vendor-specific names: liver acquisition with volume acceleration [LAVA], GE; T1 high-resolution isotropic volume excitation [THRIVE] , Philips; volumetric interpolated breath-hold examination [VIBE] , Siemens) offer the 3-dimensional acquisition of the entire liver during a single breath-hold, enabling dynamic, multiphasic MRI examinations at a high temporal and spatial resolution. 3 Although several techniques for the determination of the optimal scan delay for hepatic arterial phase imaging are available, adequate timing remains challenging. Using fixed delays, the optimal hepatic arterial phase may be missed and focal lesions with predominant arterial enhancement may be obscured. Administration of a test bolus and realtime bolus tracking are more advanced methods [4] [5] [6] ; however, these require the application of additional contrast agent, an additional scan, as well as additional training, and these are not yet readily available at every site. Furthermore, administration of the hepatobiliary contrast agent gadolinium ethoxybenzyl diethylenetriaminepentaacetic acid (Gd-EOB-DTPA) (Eovist; Bayer HealthCare, Leverkusen, Germany) requires adaptation of the acquisition protocol with regard to a shortened bolus length owing to lower injection volume and relatively higher relaxivity. 7 Advanced parallel imaging technique controlled aliasing in parallel imaging results in higher acceleration (CAIPIRINHA) allows for a considerably accelerated acquisition with maintained signal-to-noise ratio as compared with established parallel imaging techniques such as generalized autocalibrating partially parallel acquisition. 3 In an early feasibility study in a mixed patient cohort, Michaely et al 8 were able to show that the combination of VIBE imaging with CAIPIRINHA, view sharing (time-resolved angiography with interleaved stochastic trajectories [TWIST]), and Dixon fat saturation allowed for the robust acquisition of multiple hepatic arterial subphases within a single breath-hold (multiarterial CAIPIRINHA-Dixon-TWIST VIBE [MA-CDT-VIBE]).
The aim of the study was to evaluate an accelerated acquisition technique (MA-CDT-VIBE) with regard to the robustness of the hepatic arterial phase and its diagnostic accuracy for the detection of focal liver lesions at 3 T. We hypothesized that the use of CDT-VIBE with 5 hepatic arterial subphases allowed for a robust and optimized timing of the hepatic arterial phase and an improved detection of hypervascular liver lesions, as compared with a standard single arterial phase acquisition.
MATERIALS AND METHODS

Patients
This prospective single-center study obtained institutional review board approval. From June to November 2013, patients with known or suspected focal liver lesions were included consecutively. Patients not able to consent to the examination and patients with common MRI contraindications (eg, cardiac pacemakers, known adverse events related to gadolinium chelates, and terminal renal failure as indicated by a glomerular filtration rate < 30 mL/min) were excluded from the protocol. Furthermore, data sets of patients with no evidence of disease, defined as the absence of benign or malignant liver lesions, were excluded from data analysis. In total, data sets of 24 patients (13 females, 11 males; mean [SD] age, 58 [15] years) were included for image evaluation.
Magnetic Resonance Imaging
A dedicated liver examination protocol using an abdominal 18-channel body array was performed on a 3-T MRI system (MAGNETOM Skyra; Siemens Healthcare, Erlangen, Germany). The comprehensive, multiphasic MRI protocol included a dynamic T1w-3D-fs-GRE sequence with arterial, portovenous, late dynamic, and hepatobiliary phases as well as a single-shot turbo-spin echo sequence (T2 halfFourier acquisition single-shot turbo spin-echo [T2 HASTE]). Scans were performed using the hepatobiliary contrast agent Gd-EOB-DTPA (Eovist; Bayer HealthCare, Leverkusen, Germany) administered at weight-adapted doses according to the manufacturer's instructions. Table 1 displays individual sequence parameters. The arterial phase of the routine dynamic contrast-enhanced liver examination was performed with 5 hepatic arterial subphases (MA-CDT-VIBE), whereas the other sequences including the portovenous, the late dynamic, and the hepatobiliary phases were acquired as single-phase CDT-VIBE. The MA-CDT-VIBE allowed for the acquisition of 5 dynamic arterial subphases with a temporal resolution of 2.6 seconds, starting 17 seconds after manual contrast injection.
Image Evaluation
Two independent consensus readings were performed for image evaluation. In each consensus reading session, 2 experienced radiologists judged the diagnostic value of the 5 dynamic arterial phases for the detection of focal liver lesions, comparing them with the standard hepatic arterial phase. The comprehensive, multiparametric, multisequence MRI protocol served as the standard of reference for the presence of any hepatic lesions. The 2 consensus reading groups were blinded to each others' results. From the 4 Dixon data sets (ie, inphase, opposed-phase, water-only, fat-only), only the water-only images were evaluated. For comparison purposes with the standard examination protocol, the fourth of the 5 hepatic arterial subphases (acquired at 24.8 seconds after the start of contrast injection) was considered the equivalent standard arterial phase (ESAP), that is, the standard single arterial hepatic phase. Single sequences were read with regard to the number of liver lesions detected and were compared with the T2 HASTE as well as with the portovenous, late dynamic, and the hepatobiliary phases, which, in combination, served as the diagnostic criterion standard for the detection of any liver lesions. The readers noted whether they were able to detect all (yes, 1) liver lesions in any or all of the 5 multiarterial phases or the ESAP, or not (no, 2). In addition, lesions were judged as hypervascular if clear hyperintense lesion contrast enhancement in at least one of the MA-CDT-VIBE subphases was observed, and the number of hypervascular lesions per patient and for the entire cohort was noted. Furthermore, the MA-CDT-VIBE subphase with the best visual parenchymal contrast was determined. If any lesions were detected in at least one of the MA-CDT-VIBE subphases but not in the ESAP, MA-CDT-VIBE was considered to be of higher diagnostic value as compared with the standard hepatic arterial phase.
Statistical Analysis
Statistical analysis was performed using SPSS 22 (IBM Corp, Armonk, NY). Interrater agreement between the 2 consensus readings was calculated using the Cohen κ. CAIPIRINHA indicates controlled aliasing in parallel imaging results in higher acceleration; FOV, field of view; FS, fat saturation; GRAPPA, generalized autocalibrating partially parallel acquisition; CDT, CAIPIRINHA-Dixon-TWIST; HASTE, half-Fourier acquisition single-shot turbo spin-echo; MA, multiarterial; MRI, magnetic resonance imaging; PPA, partially parallel acquisition; ST, slice thickness; TA, acquisition time; TE, echo time; TR, repetition time; TWIST, timeresolved angiography with stochastic trajectories; VIBE, volume-interpolated breath-hold examination.
RESULTS
If not indicated otherwise, results refer to both consensus readings.
Technical Success and Prevalence of Liver Lesions
Every examination was considered diagnostic, and all 24 patients showed liver lesions in imaging.
Nine patients had primary liver lesions and 6 patients presented with malignant tumors (hepatocellular carcinoma [HCC], n = 3; cholangiocellular carcinoma [CCC], n = 1; biliary cystadenocarcinoma, n = 1; mixed hepatocellular-CCC, n = 1). In total, 7 malignant lesions were observed in 5 patients, and 1 patient showed disseminated HCC (defined as >10 lesions). Eight benign lesions were detected in 3 patients (focal nodular hyperplasia [FNH] , n = 2, with 1 hepatic adenoma found simultaneously; hemangioma, n = 1). Metastatic disease of the liver was detected in 15 patients, with 7 patients presenting with disseminated metastases (>10 liver metastases).
Forty-six percent (n = 11) of all lesions appeared hypervascular (HCC, FNH, metastases from neuroendocrine tumor and pancreatic cancer, each n = 2; metastases from thyroid and breast cancer as well as mixed hepatocellular-cholangiocellular carcinoma, each n = 1). Table 2 presents detailed information on patient and lesion characteristics ( Table 2) .
Consensus Reading Results
In approximately one third of the cases, MA-CDT-VIBE allowed for an improved lesion detection compared with ESAP. Detailed consensus reading results are provided in Table 3 .
Lesion Detection and Interrater Agreement
The multiparametric, multisequence MRI examination protocol (T2 HASTE, T1-weighted contrast-enhanced portovenous/late dynamic/ hepatobiliary phase) served as the standard of reference for lesion detection. Figures 1 to 4 provide examples of the dynamic, multiphasic acquisition using MA-CDT-VIBE. Evaluating the 5 MA-CDT-VIBE subphases alone, the readers were able to detect all liver lesions in 70% of the patients (first reading, 17/24) and 79% (second reading, 19/24), respectively. Excluding patients with nonhypervascular lesions, the detection rate improved to 82% (n = 9/11) and 100% (n = 11/11), respectively. In 33% (8 patients) and 25% (second reading, n = 6), MA-CDT-VIBE had an improved lesion detection rate compared with ESAP. Of these patients, 50% (first reading, n = 4) and 75% (second reading, n = 6) had hypervascular liver lesions (FNH, HCC, metastatic neuroendocrine tumor, and pancreatic cancer, each n = 1), representing 36% of all patients with hypervascular liver lesions. There was a high degree of interrater agreement regarding the diagnostic advantage of MA-CDT-VIBE (Cohen κ, 0.8; P < 0.001) and for the evaluation of the comprehensive, multiphasic imaging protocol (Cohen κ, 0.71-1.00; P < 0.001). Detailed consensus reading results are provided in Table 3 . Figures 3 and 4 show the clinical cases in which MA-CDT-VIBE proved to be advantageous over ESAP.
Parenchymal Contrast
The MA-CDT-VIBE subphase 5/5 demonstrated the best arterial lesion-to-parenchyma contrast in 79% (n = 19) of all cases, whereas subphase 4/5 (ESAP) showed the best arterial lesion-to-parenchyma contrast in 21% (n = 5) ( Table 3) . 
DISCUSSION
The CDT-VIBE is a novel, contrast-enhanced T1w-3D-fs-GRE sequence that allows for the acquisition of multiple hepatic arterial subphases during a single breath-hold (MA-CDT-VIBE). 8, 9 The MA-CDT-VIBE facilitated the timing of the arterial phase and generated additional dynamic information on the vascular status of focal liver lesions. In the present study, MA-CDT-VIBE showed an improved lesion detection rate as compared with the single, standard hepatic arterial phase, especially in patients with hypervascular liver lesions.
Optimized Contrast Timing and Hepatic Arterial Enhancement
An optimal hepatic arterial dominant phase in at least one of the MA-CDT-VIBE subphases could be obtained in all cases. Therefore, our results suggest that the use of MA-CDT-VIBE allows for an optimized timing of the hepatic arterial phase, even in a fixed-delay imaging approach. This is consistent with the most recent retrospective data demonstrating the potential of a CAIPIRINHA-Dixon-VIBE without TWIST view sharing for the reduction of motion-induced artifacts acquiring 3 hepatic arterial subphases, although at a relatively low temporal resolution of 7.5 seconds, as compared with 2.6 seconds in the present study. 10 Mori et al 11 conducted another trial to evaluate MRI with several hepatic arterial subphases. The authors examined 31 patients with HCC on a 1.5-T magnetic resonance scanner, using a T1-weighted sequence with parallel imaging (sensitivity encoding [SENSE], acceleration factor R = 2), acquiring 3 hepatic arterial subphases at a temporal resolution of 8.4 seconds. From these 3 subphases, they identified the middle subphase, acquired at 8.4 seconds after peak aortic enhancement, as optimal for HCC detection. However, the acquisition was performed with a slice thickness of 8 to 9 mm, potentially obscuring small lesions owing to partial-volume effects. On the contrary, MA-CDT-VIBE allows for a slice thickness as thin as 3 mm.
Currently, several technical approaches for an optimal timing of the hepatic arterial phase are available, for example, scanning at fixed time points or individually tailored solutions including a prescan test bolus or real-time bolus tracking. 6 For the latter, however, no consensus on what vascular reference point to use has been reached. For instance, breath-hold command and data acquisition can be started as soon as the contrast bolus reaches the aortic arch, the descending aorta, or the abdominal aorta. 5, 6, 12 In addition, real-time bolus tracking requires special training of the radiology technicians and is yet not readily available at every site. Therefore, fixed scan delay techniques can be considered more user-friendly and potentially more robust.
In general, it is assumed that the proximal abdominal aorta enhances at 17 seconds and the common hepatic artery at approximately 20 seconds after cubital intravenous contrast agent injection. 13, 14 However, several studies reported a significant variability of hepatic arterial enhancement in individual patients. 6, 15 Sharma et al 6 performed fluoroscopic T1-weighted scans in 100 consecutive patients, observing enhancement of the abdominal aorta at the level of the celiac trunk at 18.2 ± 4.1 seconds, with a range of 12 to 31 seconds. These results are in accordance with a study by Van Beers et al, 15 who investigated a population of 47 patients with hypervascular liver tumors (FNH, HCC, adenoma) and found a maximum lesion contrast-to-noise ratio at 26.5 seconds after contrast injection.
To conclude, these data underline the need for and the potential benefit of an optimally timed hepatic arterial phase achieved by a multiarterial acquisition at a high temporal resolution.
Diagnostic Accuracy and Lesion Detection
Michaely et al 8 evaluated the clinical robustness and value of CDT-VIBE with gadolinium tetra-azacyclododecane tetraacetic acid in 47 patients with various intra-abdominal malignancies, including hepatic, Two independent consensus readings judged whether all lesions could be detected (1 denotes yes; 2, no) in T2 HASTE, the portovenous/late dynamic/hepatobiliary phase, the equivalent standard arterial phase (ESAP, MA-CDT-VIBE subphase considered equivalent to the standard hepatic arterial phase), or the MA-CDT-VIBE subphase with the best lesion-to-parenchyma contrast (subphase x/5 indicated in brackets). Interrater agreement was calculated using the Cohen κ.
*Second consensus reading. †P < 0.001.
CDT indicates CAIPIRINHA-Dixon-TWIST; ESAP, equivalent standard arterial phase; HASTE, half-Fourier acquisition single-shot turbo spin-echo; HB, hepatobiliary phase; LD, late dynamic phase; MA, multiarterial; PV, portovenous phase; TWIST, time-resolved angiography with stochastic trajectories; VIBE, volume-interpolated breath-hold examination.
pancreatic, and renal lesions. Thirteen of these 47 patients had lesions within the liver, and hypervascular lesions were not specifically assessed. In the present study, we focused on the detection of focal liver lesions using the hepatocyte-specific contrast agent Gd-EOB-DTPA. Adding a steady-state, hepatobiliary phase to the comprehensive liver imaging protocol, Gd-EOB-DTPA has been shown to improve detection of focal solid hepatic lesions. 16 However, the timing of the hepatic-arterial phase in Gd-EOB-DTPA-enhanced examinations with fixed delay is challenging because only half of the contrast volume and dose is used compared with Gd-DTPA. 4 Accordingly, Zech et al 7 investigated different injection and dose regimens of Gd-EOB-DTPA in an animal model and concluded that bolus stretching by a lower injection rate compensated for the lower injection volume, maintaining a robust hepatic arterial phase. The MA-CDT-VIBE was predominantly advantageous for the detection of hypervascular lesions, such as HCC, FNH, and hypervascular metastases, and thus may potentially detect additional hypervascular lesions that could be missed in a single, standard hepatic arterial phase.
Potential Clinical Applications of MA-CDT-VIBE
Most eminently in the setting of presurgical planning and pretransplant evaluation, it is essential not to miss any HCC nodules because correct patient assignment according to the Milan Criteria is pivotal for therapy decision. 17, 18 Likewise, the use of MA-CDT-VIBE may help to detect liver metastases that demonstrate only discrete enhancement, again influencing and guiding the various therapeutic decisions and options. 19 Obviously, complete detection of all malignant lesions is of headmost importance for the correct staging of patients with cancer using established clinical tumor response criteria such as the modified Response Evaluation Criteria in Solid Tumors (mRECIST) and . This finding is consistent with data in the literature, which state that peak enhancement of hypervascular lesions such as FNH is at 26.5 seconds after intravenous contrast agent injection. 15 Histolopathological analysis confirmed the diagnosis of multifocal FNH.
therefore bears direct impact on clinical decision making. 20 For mRECIST in HCC, the longest diameter of any viable HCC lesion is assessed, with viability being defined as contrast enhancement during the arterial phase. Hence, a precise timing of the hepatic-arterial phase is even more important for an adequate response evaluation according to mRECIST. 21 In addition, the use of MA-CDT-VIBE may involve a semiquantitative or quantitative evaluation of lesion enhancement (ie, lesion perfusion) over time, using dedicated methods for signal-to-noise ratio calculations. 22 Quantitative assessment, if needed in combination with methods for breath correction, could potentially play a role in the follow-up of hypervascular lesions, for example, HCC after selective internal radiation therapy.
Respiratory Motion Artifacts
In the present cohort, marginal respiratory motion artifacts were observed in 4 patients, particularly during the later phases of the multiarterial acquisition (subphases 4/5 and 5/5). However, the diagnostic quality of the scans was not affected because the artifacts were only marginal and at least 1 arterial subphase in each of these cases prove to be artifact-free. Figure 4 shows marginal respiratory motion artifacts in subphases 4/5 and 5/5.
Despite featuring a lower temporal and spatial resolution, CAIPRINHA-Dixon-VIBE without TWIST view sharing may be superior to CDT-VIBE with regard to respiratory motion artifacts. 10 As for all keyhole techniques, a complete k-space readout is only performed during the first acquisition of the TWIST sequence. 23 If breath-induced motion occurs during the initial readout, the following acquisitions will be impaired, resulting in reduced image quality. Therefore, applicability of keyhole view-sharing techniques may be limited in uncooperative patients. However, we did not observe any severe respiratory motion artifacts in the present study.
Because particularly the late MA-CDT-VIBE subphases demonstrated to be advantageous for lesion detection, it can be argued that the acquisition of additional subphases would increase the diagnostic performance. Appending additional hepatic arterial subphases is technically feasible, as shown by Michaely et al, 8 who acquired 14 3-dimensional data sets with a temporal resolution of 2.1 seconds. However, prolonged breath-hold intervals bear the risk for respiratory motion artifacts in the late arterial phase and the following portovenous and late dynamic phases, thus potentially decreasing the diagnostic performance of the comprehensive, multisequence imaging protocol. From our experience, most patients with liver disease discover difficulty in maintaining a breath-hold for half a minute. In the present study, a breath-hold interval of 19 seconds was considered a reasonable compromise with regard to the diagnostic quality of the complete examination protocol as well as to the number and temporal resolution of the hepatic arterial phases.
Finally, a sound compromise has to be found between the necessary number of hepatic arterial phases and the number of images acquired, concerning data handling and data storing. This refers to reporting and reading of several additional data sets as well as the option for a quantitative evaluation of time-resolved MA-CDT-VIBE data sets. These issues pose some challenges for any picture archiving and communication systems and may require additional dedicated postprocessing software.
Limitations
There are several limitations to our study. First of all, the fourth of 5 arterial subphases was considered the equivalent of a single, standard hepatic arterial phase. Therefore, the diagnostic value of MA-CDT-VIBE was assessed through internal validation. However, comparison with an additional arterial standard VIBE sequence would necessitate a second MRI examination with an additional administration of contrast media. Second, the reproducibility and intraindividual variability were not assessed in this study. It remains to be elucidated how lesions appear in repeated scans and how intraindividual variability compares with the standard imaging protocol. Third, lesions of different histologic origin were evaluated in this study. Focusing on a single type of liver lesion, for example, HCC, may lead to a better understanding of the diagnostic performance of MA-CDT-VIBE. Particularly, the detection of small hypervascular type of lesions, for example, small HCC nodules or pre-HCC lesions less than 1 cm, may benefit from multiarterial acquisition.
Conclusions
In conclusion, MA-CDT-VIBE allowed for high temporal and spatial resolution of dynamic acquisition of the liver, with 5 hepatic arterial subphases being acquired during a single breath-hold. The use of MA-CDT-VIBE with 5 hepatic arterial subphases allowed for an optimized and robust timing of the hepatic arterial phase and improved the detection and differential diagnosis of hypervascular focal liver lesions.
